Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2026-05-08 Interim / Quarterly Rep…
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2026
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by QIAGEN N.V. for the quarterly period ended March 31, 2026. It includes a U.S. GAAP Quarterly Report as Exhibit 99.1, which contains condensed consolidated financial statements (balance sheets, income statements, cash flows), notes, and management discussion sections such as Operating and Financial Review and Prospects. The presence of detailed financial statements and analysis for a quarterly period indicates this is a comprehensive interim/quarterly report. The document is about 15,000 characters long, which is consistent with a full quarterly report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English
QIAGEN reports full results for Q1 2026
Interim / Quarterly Report Classification · 95% confidence The document is a detailed media release reporting full financial results for Q1 2026 for QIAGEN. It includes comprehensive financial data such as net sales, operating income, EPS, segment sales, cash flow data, and outlook for the full year and next quarter. The presence of detailed income statement information, reconciliations, and management commentary on financial performance and business trends indicates this is a quarterly financial report. The document is about 15,000 characters long, which is substantial and contains substantive financial data and analysis, not just a brief announcement or summary. It is not a preliminary earnings release (which typically contains only key highlights), but a full quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-05-07 English
Qiagen N.V., Jaarlijkse financiële verslaggeving
Annual Report Classification · 100% confidence The document is titled 'QIAGEN N.V. IFRS Annual Report 2025' and contains extensive sections including a Management Report, Financial Statements, Sustainability Statement, and Appendices. It includes detailed financial data such as Consolidated Balance Sheets, Income Statements, Cash Flows, and Notes to Financial Statements. The document also contains a Remuneration Report and an Independent Auditor's Report. The length is substantial (15,000 characters) and the content is comprehensive, covering the full fiscal year 2025. The presence of full financial statements and management discussion confirms this is the official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-30 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Earnings Release Classification · 92% confidence The document is an ad hoc announcement under the Market Abuse Regulation that provides preliminary first-quarter results and updates to the full‐year outlook, including key sales and adjusted EPS figures, without full financial statements or detailed management discussion. This corresponds to an earnings release (initial announcement of quarterly financial results). Q1 2026
2026-04-28 English
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Earnings Release Classification · 92% confidence The document is a press release announcing QIAGEN’s preliminary Q1 2026 financial results and updated full-year outlook. It provides high-level quarterly sales, EPS outlook, segment trends, and guidance details, which is characteristic of an Earnings Release rather than a full interim report, transcript, or detailed regulatory filing. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-04-28 English
QIAGEN N.V.: QIAGEN announces preliminary Q1 2026 results that achieved adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook by reducing expected net sales growth and adj. EPS
Earnings Release Classification · 93% confidence The document is an ad hoc announcement under MAR Article 17, providing preliminary Q1 2026 financial results (adjusted EPS, net sales) and updating full-year outlook. It is a high-level press‐style announcement of quarterly earnings metrics rather than a detailed interim report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-04-27 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.